Call for the next generation of talents within the interdisciplinary PhD program PharMetrX

The Graduate Research Training Program PharMetrX: Pharmacometrics & Computational Disease Modelling is an interdisciplinary PhD program bridging mathematics & pharmacy. PharMetrX aims at understanding the drug-patient-disease interaction by analysing data of drug concentration, effect & disease profiles of pre-/clinical trials and of therapeutic care by developing and applying pharmacometric (i.e. PK, PD, disease) mathematical & statistical models.

We are currently inviting applications to enrol in the PharMetrX Research+ Program or the PharMetrX Training+ Program.

The PharMetrX Research+ Program (Research & Training & Network) comprises an excellent research environment in the vibrant Berlin/Potsdam area, fascinating and innovative research projects in a highly relevant field, truly transdisciplinary working groups and supervision, an individual mentorship from one of the associated industry partner consortium, a specifically tailored training program of compact academic and industry modules, a network of 123 peers and a competitive 3.5 years fellowship.

The PharMetrX Training+ Program (Training & Network) offers a specifically tailored training program of compact academic and industry modules that convey the foundations in pharmacokinetics & pharmacodynamics, systems biology, statistics, methodological approaches of modelling & simulation etc. as well as a network of 123 peers. It is open for PhD students who have started their PhD since mid-September 2024 in the field of pharmacometrics or will do so soon.

Both programs are open to candidates with a university degree in pharmacy, pharmaceutical sciences, mathematics/statistics, bioinformatics, life sciences or medicine: see https://www.PharMetrX.de and https://www.linkedin.com/company/pharmetrx.

Deadline for applications: 06 September 2025.

Start of Module Curriculum: March 2026

PharMetrX is a joint program of Freie Universität Berlin and the Universität Potsdam, supported by a consortium of global research-driven pharmaceutical companies.

Charlotte Kloft & Wilhelm Huisinga

Program Chairs